OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) ...
The IRB is responsible for evaluating proposed research to ensure adequate provisions to protect the privacy of participants and to maintain the confidentiality of data. Research involving human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback